ANI PHARMACEUTICALS INC recently released its 10-Q report. ANI Pharmaceuticals develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally, with products that include injectables, softgel capsules, Cortrophin Gel, ILUVIEN, and YUTIQ. The company also makes oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products, and sells through wholesalers, specialty pharmacies, retail chains, distributors, mail-order houses, purchasing organizations, hospitals, and healthcare providers.
In Item 2, Management’s Discussion and Analysis, ANI said it is organized around Rare Disease, Brands, Generics, and Other businesses, and it highlighted its September 16, 2024 acquisition of Alimera, which added ILUVIEN and YUTIQ. The company said ILUVIEN now carries U.S. marketing for diabetic macular edema and chronic non-infectious uveitis affecting the posterior segment of the eye, while YUTIQ remained part of the retina franchise. It also said it operates three manufacturing facilities in Baudette, Minnesota, and East Windsor, New Jersey.
For the quarter ended March 31, 2026, net revenue rose 20.5% to $237.5 million from $197.1 million a year earlier. Operating income increased to $38.9 million from $26.2 million, and net income climbed to $29.5 million from $15.7 million.
Rare Disease and Brands revenue increased 36.3% to $128.2 million. Cortrophin Gel sales rose 42.1% to $75.1 million from $52.9 million, while ILUVIEN and YUTIQ revenue increased 19.5% to $19.3 million from $16.1 million. ANI said the Cortrophin Gel increase reflected overall ACTH market growth and market share gains, and ILUVIEN benefited from commercial and patient access initiatives established in 2025.
The Brands portfolio brought in $12.3 million, down 50.9% from $25.1 million a year earlier. ANI also recorded $21.5 million in brand royalties and other revenues, which included a $15.0 million upfront payment and about $6.5 million in associated royalties tied to the Harmony Agreement.
Generics and Other revenue increased 6.0% to $109.2 million from $103.0 million. Generic pharmaceutical products contributed $105.4 million, up 6.8%, while other generic revenues were $3.8 million, down 12.5%.
On the expense side, cost of sales rose to $93.6 million from $73.0 million. Selling, general and administrative expense fell to $73.7 million from $76.5 million, and depreciation and amortization declined to $20.9 million from $22.9 million. Research and development was essentially flat at $10.6 million versus $10.6 million a year earlier.
The company also reported a $5.8 million unrealized gain on investment in equity securities, compared with a $0.9 million loss in the prior-year quarter. Interest expense, net, improved to $3.8 million from $5.5 million, while income tax expense rose to $10.7 million from $4.3 million. As a result of these announcements, the company's shares have moved 1.04% on the market, and are now trading at a price of $84.785. Check out the company's full 10-Q submission here.
